Department of Pharmacy Services | Pharmacy and Therapeutics Committee
Formulary Review
PHARMACY &
THERAPEUTICS
Committee
Formulary Addition Request: MAHA (Make America Healthy Again), a novel policy compound with no established therapeutic indication
1Drug Identification
Product Information
2Proposed Indications
Requested Indications
Committee note: The primary indication (chronic disease) is valid. The proposed treatment does not address the primary drivers of chronic disease (obesity, smoking, alcohol, physical inactivity) and instead targets factors with no documented mortality burden (food dyes, seed oils).
3Mechanism of Action
Proposed Mechanism
MAHA operates through multiple pathways:
Executive order pathway: Bypasses standard regulatory review. Onset of action: immediate. Duration: until court injunction.
Institutional depletion pathway: Reduces capacity of regulatory agencies through workforce reduction. Half-life: years to decades (institutional knowledge, once lost, is slow to rebuild).
Public messaging pathway: Delivered via podcast, social media, and press conference. Bioavailability varies by audience credulity.
4Clinical Efficacy (Pivotal Trials)
Evidence Assessment
Manufacturer's Evidence Statement
“[The evidence] hasn't been fully gathered.”
Kennedy, Joe Rogan Experience, March 2026
Committee note: “The evidence hasn't been fully gathered” is not a standard of evidence recognized by this committee or any pharmacopoeia.
5Safety and Adverse Reactions
Documented Adverse Events (March 2026)
“The destruction that Kennedy has wrought in one year might take generations to repair.”
The Lancet, editorial, March 2025
6Cost Analysis
Direct Costs
Cost-Effectiveness Assessment
For comparison, the programs MAHA is dismantling have documented cost-effectiveness:
MAHA has provided no cost-effectiveness data. Its primary policy action has been to defund programs with proven ROI.
7Formulary Alternatives
Available Alternatives with Superior Evidence
All listed alternatives have established evidence bases, documented cost-effectiveness, and decades of real-world outcomes data. MAHA has none of these.
8Committee Discussion and Vote
Committee Discussion Summary
The committee reviewed all available evidence for MAHA, which took approximately 45 seconds, as no evidence was submitted.
The committee noted that MAHA's manufacturer described the evidence as “not fully gathered” and the FDA's own assessment was “we don't have sufficient data to establish efficacy.”
The committee further noted that the product's primary mechanism of action (institutional dismantlement) is the opposite of what a health system should stock, and that every documented outcome has been adverse.
Pharmacy and Therapeutics Committee
DO NOT ADD TO FORMULARY
0
In Favor
12
Against
0
Abstain
Unanimous. No evidence of efficacy. Unfavorable risk-benefit ratio. Active harm documented. Superior alternatives available.
Basis for Rejection
A hospital would not stock a drug with no trials, no evidence, and only adverse outcomes. A country should not either.
This page is satire formatted as a pharmaceutical document. It is not medical advice. The pharmacology, however, is real.